All In Biotech

BLA 761113 · Sanofi Aventis US

Sarclisa

Isatuximab-Irfc · Injection · CD38-directed Cytolytic Antibody

NovelOrphan

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Mar 2, 2020

Approved uses

6

Original approval plus efficacy supplements

Registered trials

107

21 Phase 3, 30 recruiting

FAERS reports

5,800

5,382 serious, 767 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 7, 2026.

SARCLISA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). SARCLISA is a CD38-directed cytolytic antibody indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. in combination with bortezomib, lenalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). ( 1 )

Mechanism: Isatuximab-irfc is an IgG1-derived monoclonal antibody that binds to CD38 expressed on the surface of hematopoietic and tumor cells, including multiple myeloma cells. Isatuximab-irfc induces apoptosis of tumor cells and activation of immune effector mechanisms including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement dependent cytotoxicity (CDC). Isatuximab-irfc inhibits the ADP-ribosyl cyclase activity of CD38. Isatuximab-irfc can activate natural killer (NK) cells in the absence of CD38-positive target tumor cells and...

Therapeutic areas: Hematology and blood cancers

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 25, 2024 Supplement 11 · Efficacy OrphanLabelLetter
  • Oct 25, 2024 Supplement 12 · Efficacy OrphanLabelLetter
  • Sep 20, 2024 Supplement 14 · Efficacy · priority review OrphanLabelLetter
  • Nov 1, 2023 Supplement 9 · Efficacy OrphanLabelLetter
  • Mar 31, 2021 Supplement 3 · Efficacy LabelLetter
  • Mar 2, 2020 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelLetterReview
2 products under this application
  • SARCLISA · ISATUXIMAB-IRFC 500MG/25ML (20MG/ML) · INJECTABLE, INJECTION · Prescription
  • SARCLISA · ISATUXIMAB-IRFC 100MG/5ML (20MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Isatuximab" as an intervention, any sponsor and status, largest first.

All 107 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • neutropenia524
  • plasma cell myeloma408
  • pneumonia386
  • thrombocytopenia330
  • covid-19306
  • pyrexia295
  • anaemia284
  • infusion related reaction260
  • diarrhoea251
  • off label use242
  • dyspnoea210
  • nausea172

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20175
201820
201962
2020353
2021680
20221,138
20231,302
2024814
2025718
2026707

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sarclisa (Isatuximab-Irfc)

2024 spending

$6.0M

Beneficiaries

74

601 claims

Per beneficiary

$81,053

$155.78 per unit

View as table
YearSpending
2020$256,912
2021$1,905,676
2022$3,413,637
2023$3,679,042
2024$5,997,930

Part B: Sarclisa (Isatuximab-Irfc) · HCPCS J9227

2024 spending

$67.9M

Beneficiaries

1,082

10,691 claims

Per beneficiary

$62,799

2024 ASP limit $77.24 per unit

View as table
YearSpending
2020$5,821,763
2021$28,633,447
2022$42,512,757
2023$54,190,478
2024$67,948,017

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 88 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.